BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25:1054-1062.e5. [PMID: 28467925 DOI: 10.1016/j.cmet.2017.04.001] [Cited by in Crossref: 349] [Cited by in F6Publishing: 334] [Article Influence: 87.3] [Reference Citation Analysis]
Number Citing Articles
1 Malnick S, Maor Y. The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome. Visc Med 2020;36:198-205. [PMID: 32775350 DOI: 10.1159/000507233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
3 Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305-315. [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013] [Cited by in Crossref: 190] [Cited by in F6Publishing: 176] [Article Influence: 38.0] [Reference Citation Analysis]
4 Hullar MAJ, Jenkins IC, Randolph TW, Curtis KR, Monroe KR, Ernst T, Shepherd JA, Stram DO, Cheng I, Kristal BS, Wilkens LR, Franke A, Le Marchand L, Lim U, Lampe JW. Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study. Gut Microbes 2021;13:1965463. [PMID: 34491886 DOI: 10.1080/19490976.2021.1965463] [Reference Citation Analysis]
5 Lou J, Jiang Y, Rao B, Li A, Ding S, Yan H, Zhou H, Liu Z, Shi Q, Cui G, Yu Z, Ren Z. Fecal Microbiomes Distinguish Patients With Autoimmune Hepatitis From Healthy Individuals. Front Cell Infect Microbiol 2020;10:342. [PMID: 32850468 DOI: 10.3389/fcimb.2020.00342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
7 Yoshio S, Kanto T. Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunol Med 2021;44:175-86. [PMID: 33444517 DOI: 10.1080/25785826.2020.1868664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Song M, Yuan F, Li X, Ma X, Yin X, Rouchka EC, Zhang X, Deng Z, Prough RA, McClain CJ. Analysis of sex differences in dietary copper-fructose interaction-induced alterations of gut microbial activity in relation to hepatic steatosis.Biol Sex Differ. 2021;12:3. [PMID: 33407877 DOI: 10.1186/s13293-020-00346-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461-78. [DOI: 10.1038/s41575-018-0014-9] [Cited by in Crossref: 153] [Cited by in F6Publishing: 144] [Article Influence: 38.3] [Reference Citation Analysis]
10 Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L. Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol 2019; 25(30): 4199-4212 [PMID: 31435173 DOI: 10.3748/wjg.v25.i30.4199] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
11 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
12 Hsu CL, Duan Y, Fouts DE, Schnabl B. Intestinal virome and therapeutic potential of bacteriophages in liver disease. J Hepatol 2021:S0168-8278(21)01997-8. [PMID: 34437908 DOI: 10.1016/j.jhep.2021.08.003] [Reference Citation Analysis]
13 Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal Barrier in Human Health and Disease. Int J Environ Res Public Health 2021;18:12836. [PMID: 34886561 DOI: 10.3390/ijerph182312836] [Reference Citation Analysis]
14 Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiol Genomics 2021;53:336-48. [PMID: 34151600 DOI: 10.1152/physiolgenomics.00011.2021] [Reference Citation Analysis]
15 [DOI: 10.1101/2020.08.06.240655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Tang Y, Zhang J, Li J, Lei X, Xu D, Wang Y, Li C, Li X, Mao Y. Turnover of bile acids in liver, serum and caecal content by high-fat diet feeding affects hepatic steatosis in rats. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019;1864:1293-304. [DOI: 10.1016/j.bbalip.2019.05.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
17 Park SY, Hwang BO, Lim M, Ok SH, Lee SK, Chun KS, Park KK, Hu Y, Chung WY, Song NY. Oral-Gut Microbiome Axis in Gastrointestinal Disease and Cancer. Cancers (Basel) 2021;13:2124. [PMID: 33924899 DOI: 10.3390/cancers13092124] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Wang JK, Yao SK. Roles of Gut Microbiota and Metabolites in Pathogenesis of Functional Constipation. Evid Based Complement Alternat Med 2021;2021:5560310. [PMID: 34603471 DOI: 10.1155/2021/5560310] [Reference Citation Analysis]
19 Mann JP, Vreugdenhil A, Socha P, Jańczyk W, Baumann U, Rajwal S, Casswall T, Marcus C, van Mourik I, O'rahilly S, Savage DB, Noble-jamieson G, Lacaille F, Dabbas M, Dubern B, Kelly DA, Nobili V, Anstee QM. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemporary Clinical Trials 2018;75:67-71. [DOI: 10.1016/j.cct.2018.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
20 Singh SP, Barik RK. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet? J Clin Exp Hepatol 2020;10:88-98. [PMID: 32025168 DOI: 10.1016/j.jceh.2019.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
21 Caussy C, Hsu C, Singh S, Bassirian S, Kolar J, Faulkner C, Sinha N, Bettencourt R, Gara N, Valasek MA, Schnabl B, Richards L, Brenner DA, Hofmann AF, Loomba R. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther 2019;49:183-93. [PMID: 30506692 DOI: 10.1111/apt.15035] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
22 Rao BC, Lou JM, Wang WJ, Li A, Cui GY, Yu ZJ, Ren ZG. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2020;19:109-15. [PMID: 32037278 DOI: 10.1016/j.hbpd.2020.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Gui QF, Jin HL, Zhu F, Lu HF, Zhang Q, Xu J, Yang YM, Xiao C. Gut microbiota signatures in Schistosoma japonicum infection-induced liver cirrhosis patients: a case-control study. Infect Dis Poverty 2021;10:43. [PMID: 33771232 DOI: 10.1186/s40249-021-00821-8] [Reference Citation Analysis]
24 Burz SD, Abraham AL, Fonseca F, David O, Chapron A, Béguet-Crespel F, Cénard S, Le Roux K, Patrascu O, Levenez F, Schwintner C, Blottière HM, Béra-Maillet C, Lepage P, Doré J, Juste C. A Guide for Ex Vivo Handling and Storage of Stool Samples Intended for Fecal Microbiota Transplantation. Sci Rep 2019;9:8897. [PMID: 31222022 DOI: 10.1038/s41598-019-45173-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
25 Duarte SMB, Stefano JT, Oliveira CP. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Ann Hepatol 2019;18:416-21. [PMID: 31036494 DOI: 10.1016/j.aohep.2019.04.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
26 Ma L, Li H, Hu J, Zheng J, Zhou J, Botchlett R, Matthews D, Zeng T, Chen L, Xiao X, Athrey G, Threadgill DW, Li Q, Glaser S, Francis H, Meng F, Li Q, Alpini G, Wu C. Indole Alleviates Diet-Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3. Hepatology 2020;72:1191-203. [PMID: 31953865 DOI: 10.1002/hep.31115] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
27 Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. J Hepatol. 2018;68:238-250. [PMID: 29154966 DOI: 10.1016/j.jhep.2017.11.012] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 32.0] [Reference Citation Analysis]
28 Yamazaki K, Kato T, Tsuboi Y, Miyauchi E, Suda W, Sato K, Nakajima M, Yokoji-Takeuchi M, Yamada-Hara M, Tsuzuno T, Matsugishi A, Takahashi N, Tabeta K, Miura N, Okuda S, Kikuchi J, Ohno H, Yamazaki K. Oral Pathobiont-Induced Changes in Gut Microbiota Aggravate the Pathology of Nonalcoholic Fatty Liver Disease in Mice. Front Immunol 2021;12:766170. [PMID: 34707622 DOI: 10.3389/fimmu.2021.766170] [Reference Citation Analysis]
29 Gleeson MW. Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia. Curr Treat Options Gastro 2019;17:378-93. [DOI: 10.1007/s11938-019-00241-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Caussy C, Tripathi A, Humphrey G, Bassirian S, Singh S, Faulkner C, Bettencourt R, Rizo E, Richards L, Xu ZZ, Downes MR, Evans RM, Brenner DA, Sirlin CB, Knight R, Loomba R. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 2019;10:1406. [PMID: 30926798 DOI: 10.1038/s41467-019-09455-9] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 28.0] [Reference Citation Analysis]
31 Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther 2019;50:144-58. [PMID: 31149745 DOI: 10.1111/apt.15314] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
32 Ortigão R, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D. Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. GE Port J Gastroenterol 2020;27:336-51. [PMID: 32999906 DOI: 10.1159/000505036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tilg H, Burcelin R, Tremaroli V. Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis? Gut 2020;69:1373-4. [PMID: 32060128 DOI: 10.1136/gutjnl-2019-320490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Deng YD, Peng XB, Zhao RR, Ma CQ, Li JN, Yao LQ. The intestinal microbial community dissimilarity in hepatitis B virus-related liver cirrhosis patients with and without at alcohol consumption. Gut Pathog. 2019;11:58. [PMID: 31788031 DOI: 10.1186/s13099-019-0337-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
35 Niederreiter L, Tilg H. Cytokines and fatty liver diseases. Liver Research 2018;2:14-20. [DOI: 10.1016/j.livres.2018.03.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 7.8] [Reference Citation Analysis]
36 Mun SJ, Lee J, Chung KS, Son MY, Son MJ. Effect of Microbial Short-Chain Fatty Acids on CYP3A4-Mediated Metabolic Activation of Human Pluripotent Stem Cell-Derived Liver Organoids. Cells 2021;10:126. [PMID: 33440728 DOI: 10.3390/cells10010126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Hoyles L, Fernández-Real JM, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH, Chilloux J, Myridakis A, Martinez-Gili L, Moreno-Navarrete JM, Benhamed F, Azalbert V, Blasco-Baque V, Puig J, Xifra G, Ricart W, Tomlinson C, Woodbridge M, Cardellini M, Davato F, Cardolini I, Porzio O, Gentileschi P, Lopez F, Foufelle F, Butcher SA, Holmes E, Nicholson JK, Postic C, Burcelin R, Dumas ME. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 2018;24:1070-80. [PMID: 29942096 DOI: 10.1038/s41591-018-0061-3] [Cited by in Crossref: 214] [Cited by in F6Publishing: 197] [Article Influence: 53.5] [Reference Citation Analysis]
38 Challa TD, Wueest S, Lucchini FC, Dedual M, Modica S, Borsigova M, Wolfrum C, Blüher M, Konrad D. Liver ASK1 protects from non-alcoholic fatty liver disease and fibrosis. EMBO Mol Med 2019;11:e10124. [PMID: 31595673 DOI: 10.15252/emmm.201810124] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
39 Tierney BT, Tan Y, Kostic AD, Patel CJ. Gene-level metagenomic architectures across diseases yield high-resolution microbiome diagnostic indicators. Nat Commun 2021;12:2907. [PMID: 34006865 DOI: 10.1038/s41467-021-23029-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Ji Y, Yin Y, Sun L, Zhang W. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. Int J Mol Sci 2020;21:E3066. [PMID: 32357561 DOI: 10.3390/ijms21093066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
41 Chen S, Guo H, Xie M, Zhou C, Zheng M. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease. Int Immunopharmacol 2021;97:107609. [PMID: 33887577 DOI: 10.1016/j.intimp.2021.107609] [Reference Citation Analysis]
42 Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019;20:461-472. [PMID: 31707624 DOI: 10.1007/s11154-019-09512-0] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 49.5] [Reference Citation Analysis]
43 Marrero I, Maricic I, Feldstein AE, Loomba R, Schnabl B, Rivera-Nieves J, Eckmann L, Kumar V. Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. Front Immunol 2018;9:2082. [PMID: 30254647 DOI: 10.3389/fimmu.2018.02082] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
44 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Reference Citation Analysis]
45 Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep 2021;3:100284. [PMID: 34027340 DOI: 10.1016/j.jhepr.2021.100284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Nobs SP, Tuganbaev T, Elinav E. Microbiome diurnal rhythmicity and its impact on host physiology and disease risk. EMBO Rep 2019;20:e47129. [PMID: 30877136 DOI: 10.15252/embr.201847129] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
47 Kwong EK, Puri P. Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease. Transl Gastroenterol Hepatol 2021;6:3. [PMID: 33409398 DOI: 10.21037/tgh.2020.02.18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
48 Gao B, Chi L, Zhu Y, Shi X, Tu P, Li B, Yin J, Gao N, Shen W, Schnabl B. An Introduction to Next Generation Sequencing Bioinformatic Analysis in Gut Microbiome Studies. Biomolecules 2021;11:530. [PMID: 33918473 DOI: 10.3390/biom11040530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Reference Citation Analysis]
50 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
51 Takahashi H, Kotani K, Tanaka K, Egucih Y, Anzai K. Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms. Front Endocrinol (Lausanne). 2018;9:588. [PMID: 30374329 DOI: 10.3389/fendo.2018.00588] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
52 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 742] [Article Influence: 194.3] [Reference Citation Analysis]
53 Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M, Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Endotoxins and Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:770986. [PMID: 34777261 DOI: 10.3389/fendo.2021.770986] [Reference Citation Analysis]
54 Adenote A, Dumic I, Madrid C, Barusya C, Nordstrom CW, Rueda Prada L. NAFLD and Infection, a Nuanced Relationship. Can J Gastroenterol Hepatol 2021;2021:5556354. [PMID: 33977096 DOI: 10.1155/2021/5556354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Chen L, Cao G, Wang M, Feng YL, Chen DQ, Vaziri ND, Zhuang S, Zhao YY. The Matrix Metalloproteinase-13 Inhibitor Poricoic Acid ZI Ameliorates Renal Fibrosis by Mitigating Epithelial-Mesenchymal Transition. Mol Nutr Food Res 2019;:e1900132. [PMID: 30925007 DOI: 10.1002/mnfr.201900132] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
56 Albhaisi SAM, Bajaj JS. The Influence of the Microbiome on NAFLD and NASH. Clin Liver Dis (Hoboken) 2021;17:15-8. [PMID: 33552480 DOI: 10.1002/cld.1010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Morikawa R, Nakamoto N, Amiya T, Chu PS, Koda Y, Teratani T, Suzuki T, Kurebayashi Y, Ueno A, Taniki N, Miyamoto K, Yamaguchi A, Shiba S, Katayama T, Yoshida K, Takada Y, Ishihara R, Ebinuma H, Sakamoto M, Kanai T. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. J Hepatol 2021;74:511-21. [PMID: 33038434 DOI: 10.1016/j.jhep.2020.09.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
58 Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Reference Citation Analysis]
59 Li H, Wang Q, Chen P, Zhou C, Zhang X, Chen L. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Front Pharmacol 2021;12:788558. [PMID: 34938193 DOI: 10.3389/fphar.2021.788558] [Reference Citation Analysis]
60 Fei N, Bruneau A, Zhang X, Wang R, Wang J, Rabot S, Gérard P, Zhao L. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. mBio 2020;11:e03263-19. [PMID: 32019793 DOI: 10.1128/mBio.03263-19] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
61 Altay O, Nielsen J, Uhlen M, Boren J, Mardinoglu A. Systems biology perspective for studying the gut microbiota in human physiology and liver diseases. EBioMedicine 2019;49:364-73. [PMID: 31636011 DOI: 10.1016/j.ebiom.2019.09.057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
62 Su Y, He L, Hu Z, Li Y, Zhang Y, Fan Z, Zhao K, Zhang H, Liu C. Obesity Causes Abrupt Changes in the Testicular Microbiota and Sperm Motility of Zebrafish. Front Immunol 2021;12:639239. [PMID: 34248933 DOI: 10.3389/fimmu.2021.639239] [Reference Citation Analysis]
63 Sharpton SR, Ajmera V, Loomba R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin Gastroenterol Hepatol 2019;17:296-306. [PMID: 30196156 DOI: 10.1016/j.cgh.2018.08.065] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 15.5] [Reference Citation Analysis]
64 Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejsek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms 2021;9:957. [PMID: 33946843 DOI: 10.3390/microorganisms9050957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
65 Bisht V, Acharjee A, Gkoutos GV. NFnetFu: A novel workflow for microbiome data fusion. Comput Biol Med 2021;135:104556. [PMID: 34216888 DOI: 10.1016/j.compbiomed.2021.104556] [Reference Citation Analysis]
66 Wang B, Wang L, Wang H, Dai H, Lu X, Lee YK, Gu Z, Zhao J, Zhang H, Chen W, Wang G. Targeting the Gut Microbiota for Remediating Obesity and Related Metabolic Disorders. J Nutr 2021;151:1703-16. [PMID: 33982127 DOI: 10.1093/jn/nxab103] [Reference Citation Analysis]
67 Kriss M, Hazleton KZ, Nusbacher NM, Martin CG, Lozupone CA. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol. 2018;44:34-40. [PMID: 30036705 DOI: 10.1016/j.mib.2018.07.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 26.3] [Reference Citation Analysis]
68 Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019;76:1541-58. [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 33.7] [Reference Citation Analysis]
69 Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M, Timpson P. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. Gastroenterology 2018;154:820-38. [PMID: 29287624 DOI: 10.1053/j.gastro.2017.11.280] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 19.6] [Reference Citation Analysis]
70 Demir M, Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Scholz CJ, Kretzschmar A, Roderburg C, Lammert F, Goeser T, Kasper P, Steffen HM. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time? J Gastroenterol Hepatol 2020;35:1969-77. [PMID: 32267559 DOI: 10.1111/jgh.15071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
71 Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, Penna G, Rescigno M. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216-1228. [PMID: 31419514 DOI: 10.1016/j.jhep.2019.08.005] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 34.3] [Reference Citation Analysis]
72 Albhaisi S, Sanyal AJ. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:665987. [PMID: 34040583 DOI: 10.3389/fendo.2021.665987] [Reference Citation Analysis]
73 Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Res. 2018;2:43-51. [PMID: 30416839 DOI: 10.1016/j.livres.2017.11.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
74 Kang GU, Jung DR, Lee YH, Jeon SY, Han HS, Chong GO, Shin JH. Dynamics of Fecal Microbiota with and without Invasive Cervical Cancer and Its Application in Early Diagnosis. Cancers (Basel) 2020;12:E3800. [PMID: 33339445 DOI: 10.3390/cancers12123800] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Fiorucci S, Biagioli M, Distrutti E. Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res 2018;134:289-98. [PMID: 30021122 DOI: 10.1016/j.phrs.2018.07.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
76 Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol 2020;5:996-1007. [PMID: 32805205 DOI: 10.1016/S2468-1253(20)30216-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
77 Quesada-Vázquez S, Aragonès G, Del Bas JM, Escoté X. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis. Cells 2020;9:E176. [PMID: 31936799 DOI: 10.3390/cells9010176] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
78 Bárcena C, Valdés-Mas R, Mayoral P, Garabaya C, Durand S, Rodríguez F, Fernández-García MT, Salazar N, Nogacka AM, Garatachea N, Bossut N, Aprahamian F, Lucia A, Kroemer G, Freije JMP, Quirós PM, López-Otín C. Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. Nat Med 2019;25:1234-42. [PMID: 31332389 DOI: 10.1038/s41591-019-0504-5] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 34.0] [Reference Citation Analysis]
79 Wang M, Chen G, Chen D, Ye H, Sun Y, Zeng X, Liu Z. Purified fraction of polysaccharides from Fuzhuan brick tea modulates the composition and metabolism of gut microbiota in anaerobic fermentation in vitro. Int J Biol Macromol 2019;140:858-70. [PMID: 31446105 DOI: 10.1016/j.ijbiomac.2019.08.187] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
80 Tincopa MA. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00177. [PMID: 33102798 DOI: 10.1002/edm2.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Castillo-Castro C, Martagón-Rosado AJ, Ortiz-Lopez R, Garrido-Treviño LF, Villegas-Albo M, Bosques-Padilla FJ. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World J Hepatol 2021; 13(11): 1494-1511 [PMID: 34904026 DOI: 10.4254/wjh.v13.i11.1494] [Reference Citation Analysis]
82 Derovs A, Laivacuma S, Krumina A. Targeting Microbiota: What Do We Know about It at Present? Medicina (Kaunas) 2019;55:E459. [PMID: 31405111 DOI: 10.3390/medicina55080459] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
83 Wang L, Chen T, Wang H, Wu X, Cao Q, Wen K, Deng KY, Xin H. Engineered Bacteria of MG1363-pMG36e-GLP-1 Attenuated Obesity-Induced by High Fat Diet in Mice. Front Cell Infect Microbiol 2021;11:595575. [PMID: 33732656 DOI: 10.3389/fcimb.2021.595575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.Gastroenterology. 2020;159:1839-1852. [PMID: 32652145 DOI: 10.1053/j.gastro.2020.07.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
85 Chen X, Yu J, Xue C, Wang Y, Tang Q, Mao X. Mechanism of neoagarotetraose protects against intense exercise-induced liver injury based on molecular ecological network analysis. Bioscience, Biotechnology, and Biochemistry 2019;83:1227-38. [DOI: 10.1080/09168451.2019.1607246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
86 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Hartmann P, Schnabl B. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2021;41:87-102. [PMID: 33957682 DOI: 10.1055/s-0040-1719174] [Reference Citation Analysis]
88 You E, Ko P, Jeong J, Keum S, Kim JW, Seo YJ, Song WK, Rhee S. Dynein-mediated nuclear translocation of yes-associated protein through microtubule acetylation controls fibroblast activation. Cell Mol Life Sci 2020;77:4143-61. [PMID: 31912196 DOI: 10.1007/s00018-019-03412-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
90 Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Maeda A, Tanaka Y, Nakajima S, Ohno H, Usuda H, Kawanaka M, Kawaguchi T, Torimura T, Kage M, Hyogo H, Takahashi H, Eguchi Y, Aishima S, Wada K, Kobayashi N, Sumida Y, Saito S, Nakajima A. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:2275-84. [PMID: 33709477 DOI: 10.1111/jgh.15487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
91 Thomas H. A gut microbiome signature for advanced fibrosis diagnosis in NAFLD. Nat Rev Gastroenterol Hepatol 2017;14:388-388. [DOI: 10.1038/nrgastro.2017.67] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
92 Li X, Watanabe K, Kimura I. Gut Microbiota Dysbiosis Drives and Implies Novel Therapeutic Strategies for Diabetes Mellitus and Related Metabolic Diseases. Front Immunol. 2017;8:1882. [PMID: 29326727 DOI: 10.3389/fimmu.2017.01882] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 13.8] [Reference Citation Analysis]
93 Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Bilson J, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2020;158:1597-1610. [PMID: 31987796 DOI: 10.1053/j.gastro.2020.01.031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
94 Friedman ES, Li Y, Shen TD, Jiang J, Chau L, Adorini L, Babakhani F, Edwards J, Shapiro D, Zhao C, Carr RM, Bittinger K, Li H, Wu GD. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid. Gastroenterology. 2018;155:1741-1752.e5. [PMID: 30144429 DOI: 10.1053/j.gastro.2018.08.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
95 Le Goallec A, Tierney BT, Luber JM, Cofer EM, Kostic AD, Patel CJ. A systematic machine learning and data type comparison yields metagenomic predictors of infant age, sex, breastfeeding, antibiotic usage, country of origin, and delivery type. PLoS Comput Biol 2020;16:e1007895. [PMID: 32392251 DOI: 10.1371/journal.pcbi.1007895] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
96 Zhang S, Zhao J, Xie F, He H, Johnston LJ, Dai X, Wu C, Ma X. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. Obes Rev 2021;:e13316. [PMID: 34279051 DOI: 10.1111/obr.13316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
97 Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280-295. [PMID: 29154964 DOI: 10.1016/j.jhep.2017.11.014] [Cited by in Crossref: 257] [Cited by in F6Publishing: 247] [Article Influence: 51.4] [Reference Citation Analysis]
98 Lang S, Schnabl B. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. Cell Host Microbe 2020;28:233-44. [PMID: 32791115 DOI: 10.1016/j.chom.2020.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 20.0] [Reference Citation Analysis]
99 Castaño-Rodríguez N, Mitchell HM, Kaakoush NO. NAFLD, Helicobacter species and the intestinal microbiome. Best Pract Res Clin Gastroenterol 2017;31:657-68. [PMID: 29566909 DOI: 10.1016/j.bpg.2017.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
100 Ahlawat S, Asha, Sharma KK. Gut-organ axis: a microbial outreach and networking. Lett Appl Microbiol 2021;72:636-68. [PMID: 32472555 DOI: 10.1111/lam.13333] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
101 Su H, Liu J, Wu G, Long Z, Fan J, Xu Z, Liu J, Yu Z, Cao M, Liao N, Peng J, Yu W, Li W, Wu H, Wang X. Homeostasis of gut microbiota protects against polychlorinated biphenyl 126-induced metabolic dysfunction in liver of mice. Science of The Total Environment 2020;720:137597. [DOI: 10.1016/j.scitotenv.2020.137597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Liu K, Yang J, Yuan H. Recent progress in research on the gut microbiota and highland adaptation on the Qinghai-Tibet Plateau. J Evol Biol 2021;34:1514-30. [PMID: 34473899 DOI: 10.1111/jeb.13924] [Reference Citation Analysis]
103 Federici M. Our second genome and the impact on metabolic disorders: why gut microbiome is an important player in diabetes and associated abnormalities. Acta Diabetol 2019;56:491-2. [DOI: 10.1007/s00592-019-01315-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
104 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
105 Kim JY, Garcia-Carbonell R, Yamachika S, Zhao P, Dhar D, Loomba R, Kaufman RJ, Saltiel AR, Karin M. ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P. Cell 2018;175:133-145.e15. [PMID: 30220454 DOI: 10.1016/j.cell.2018.08.020] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 23.0] [Reference Citation Analysis]
106 Lee YH, Kang GU, Jeon SY, Tagele SB, Pham HQ, Kim MS, Ahmad S, Jung DR, Park YJ, Han HS, Shin JH, Chong GO. Vaginal Microbiome-Based Bacterial Signatures for Predicting the Severity of Cervical Intraepithelial Neoplasia. Diagnostics (Basel) 2020;10:E1013. [PMID: 33256024 DOI: 10.3390/diagnostics10121013] [Reference Citation Analysis]
107 Mantovani A, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of Kidney Dysfunction IN Nafld. CPD 2020;26:1045-61. [DOI: 10.2174/1381612825666191026113119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
108 Jadhav K, Cohen TS. Can You Trust Your Gut? Front Endocrinol (Lausanne). 2020;11:592157. [PMID: 33193105 DOI: 10.3389/fendo.2020.592157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
109 Li Z, Ni M, Yu H, Wang L, Zhou X, Chen T, Liu G, Gao Y. Gut Microbiota and Liver Fibrosis: One Potential Biomarker for Predicting Liver Fibrosis. Biomed Res Int 2020;2020:3905130. [PMID: 32685479 DOI: 10.1155/2020/3905130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
110 He LH, Yao DH, Wang LY, Zhang L, Bai XL. Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Front Microbiol 2021;12:761836. [PMID: 34795655 DOI: 10.3389/fmicb.2021.761836] [Reference Citation Analysis]
111 Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol. 2020;318:G554-G573. [PMID: 31984784 DOI: 10.1152/ajpgi.00223.2019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
112 Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(17): 2019-2028 [PMID: 31114130 DOI: 10.3748/wjg.v25.i17.2019] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
113 Dong TS, Jacobs JP. Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? Exp Biol Med (Maywood) 2019;244:408-18. [PMID: 30871368 DOI: 10.1177/1535370219836739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
114 Manne V, Handa P, Kowdley KV. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:23-37. [PMID: 29128059 DOI: 10.1016/j.cld.2017.08.007] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 16.2] [Reference Citation Analysis]
115 Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res 2019;209:22-38. [PMID: 30853445 DOI: 10.1016/j.trsl.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
116 Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology. 2021;73:833-842. [PMID: 32780879 DOI: 10.1002/hep.31518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 35.0] [Reference Citation Analysis]
117 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
118 Roychowdhury S, Selvakumar PC, Cresci GAM. The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. Med Sci (Basel) 2018;6:E47. [PMID: 29874807 DOI: 10.3390/medsci6020047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
119 Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, Beyersdorf N, Dandekar T, Rosenstiel P, Geier A. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J. 2018;6:1496-1507. [PMID: 30574320 DOI: 10.1177/2050640618804444] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 13.5] [Reference Citation Analysis]
120 Maricic I, Marrero I, Eguchi A, Nakamura R, Johnson CD, Dasgupta S, Hernandez CD, Nguyen PS, Swafford AD, Knight R, Feldstein AE, Loomba R, Kumar V. Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis. J Immunol 2018;201:3017-35. [PMID: 30322964 DOI: 10.4049/jimmunol.1800614] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
121 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
122 Meng G, Wang M, Zhou L, Yu L, Jiang H. Reply: The emergence of clarifying the role of gut microbes in arrhythmia. Int J Cardiol 2018;271:122. [PMID: 30223344 DOI: 10.1016/j.ijcard.2018.05.119] [Reference Citation Analysis]
123 Mayneris-Perxachs J, Cardellini M, Hoyles L, Latorre J, Davato F, Moreno-Navarrete JM, Arnoriaga-Rodríguez M, Serino M, Abbott J, Barton RH, Puig J, Fernández-Real X, Ricart W, Tomlinson C, Woodbridge M, Gentileschi P, Butcher SA, Holmes E, Nicholson JK, Pérez-Brocal V, Moya A, Clain DM, Burcelin R, Dumas ME, Federici M, Fernández-Real JM. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Microbiome 2021;9:104. [PMID: 33962692 DOI: 10.1186/s40168-021-01052-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Martín-Mateos R, Albillos A. The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. Front Immunol 2021;12:660179. [PMID: 33936094 DOI: 10.3389/fimmu.2021.660179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
125 Rattan P, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. Liver Transpl. 2020;26:1316-1327. [PMID: 32564483 DOI: 10.1002/lt.25828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
126 Jasirwan COM, Muradi A, Hasan I, Simadibrata M, Rinaldi I. Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota Food Health 2021;40:50-8. [PMID: 33520569 DOI: 10.12938/bmfh.2020-046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
127 Ni Y, Ni L, Zhuge F, Fu Z. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2020;64:e2000375. [PMID: 32738185 DOI: 10.1002/mnfr.202000375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
128 White LS, Van den Bogaerde J, Kamm M. The gut microbiota: cause and cure of gut diseases. Med J Aust 2018;209:312-7. [PMID: 30257633 DOI: 10.5694/mja17.01067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Mikó E, Kovács T, Sebő É, Tóth J, Csonka T, Ujlaki G, Sipos A, Szabó J, Méhes G, Bai P. Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored. Cells 2019;8:E293. [PMID: 30934972 DOI: 10.3390/cells8040293] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
130 Soon G, Wee A. Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. Clin Mol Hepatol 2021;27:44-57. [PMID: 33207115 DOI: 10.3350/cmh.2020.0181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
131 Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020;69:1343-52. [PMID: 32066623 DOI: 10.1136/gutjnl-2018-317593] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 19.5] [Reference Citation Analysis]
132 Simbrunner B, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. World J Gastroenterol 2019; 25(39): 5897-5917 [PMID: 31660028 DOI: 10.3748/wjg.v25.i39.5897] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
133 Gupta M, Krishan P, Kaur A, Arora S, Trehanpati N, Singh TG, Bedi O. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD. Inflamm Res 2021;70:765-76. [PMID: 34212214 DOI: 10.1007/s00011-021-01480-z] [Reference Citation Analysis]
134 Hodges JK, Sasaki GY, Bruno RS. Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies. J Nutr Biochem 2020;85:108478. [PMID: 32801031 DOI: 10.1016/j.jnutbio.2020.108478] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
135 Hoozemans J, de Brauw M, Nieuwdorp M, Gerdes V. Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. Metabolites 2021;11:353. [PMID: 34072995 DOI: 10.3390/metabo11060353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Nishimura N, Kaji K, Kitagawa K, Sawada Y, Furukawa M, Ozutsumi T, Fujinaga Y, Tsuji Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Fukui H, Yoshiji H. Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. Int J Mol Sci 2021;22:6921. [PMID: 34203178 DOI: 10.3390/ijms22136921] [Reference Citation Analysis]
137 Tacke F, Weiskirchen R. An update on the recent advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol. 2018;12:1143-1152. [PMID: 30261763 DOI: 10.1080/17474124.2018.1530110] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
138 Lee Y, Lee HY. Revisiting the Bacterial Phylum Composition in Metabolic Diseases Focused on Host Energy Metabolism. Diabetes Metab J. 2020;44:658-667. [PMID: 32662252 DOI: 10.4093/dmj.2019.0220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
139 Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. Int J Mol Sci 2021;22:7800. [PMID: 34360566 DOI: 10.3390/ijms22157800] [Reference Citation Analysis]
140 Martínez-Montoro JI, Kuchay MS, Balaguer-Román A, Martínez-Sánchez MA, Frutos MD, Fernández-García JC, Ramos-Molina B. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. Obes Rev 2021;:e13367. [PMID: 34729904 DOI: 10.1111/obr.13367] [Reference Citation Analysis]
141 Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. Front Med (Lausanne) 2020;7:361. [PMID: 32850884 DOI: 10.3389/fmed.2020.00361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
142 Bergheim I, Schuppan D. Microbiome and Diseases: Hepatic Disorders. In: Haller D, editor. The Gut Microbiome in Health and Disease. Cham: Springer International Publishing; 2018. pp. 279-93. [DOI: 10.1007/978-3-319-90545-7_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Ribeiro MF, Santos AA, Afonso MB, Rodrigues PM, Sá Santos S, Castro RE, Rodrigues CMP, Solá S. Diet-dependent gut microbiota impacts on adult neurogenesis through mitochondrial stress modulation. Brain Commun 2020;2:fcaa165. [PMID: 33426525 DOI: 10.1093/braincomms/fcaa165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
144 Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr Diab Rep 2021;21:15. [PMID: 33742318 DOI: 10.1007/s11892-021-01383-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Reference Citation Analysis]
146 Takahashi S, Luo Y, Ranjit S, Xie C, Libby AE, Orlicky DJ, Dvornikov A, Wang XX, Myakala K, Jones BA, Bhasin K, Wang D, McManaman JL, Krausz KW, Gratton E, Ir D, Robertson CE, Frank DN, Gonzalez FJ, Levi M. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice. J Biol Chem 2020;295:4733-47. [PMID: 32075905 DOI: 10.1074/jbc.RA119.011913] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
147 Hyun CK. Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:9139. [PMID: 34502047 DOI: 10.3390/ijms22179139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
148 Paul J. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00043-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
149 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
150 Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 2021;:1-11. [PMID: 34904923 DOI: 10.1080/14728222.2021.2018418] [Reference Citation Analysis]
151 Puri P, Sanyal AJ. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2018;22:121-32. [PMID: 29128052 DOI: 10.1016/j.cld.2017.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
152 Shi J, Yang Y, Xu W, Cai H, Wu J, Long J, Cai Q, Zheng W, Flynn CR, Shu XO, Yu D. Sex-Specific Associations between Gut Microbiome and Non-Alcoholic Fatty Liver Disease among Urban Chinese Adults. Microorganisms 2021;9:2118. [PMID: 34683439 DOI: 10.3390/microorganisms9102118] [Reference Citation Analysis]
153 He Q, Hou Q, Wang Y, Shen L, Sun Z, Zhang H, Liong M, Kwok L. Long-term administration of Lactobacillus casei Zhang stabilized gut microbiota of adults and reduced gut microbiota age index of older adults. Journal of Functional Foods 2020;64:103682. [DOI: 10.1016/j.jff.2019.103682] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
154 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
156 Ko M, Kamimura K, Owaki T, Nagoya T, Sakai N, Nagayama I, Niwa Y, Shibata O, Oda C, Morita S, Kimura A, Inoue R, Setsu T, Sakamaki A, Yokoo T, Terai S. Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver. Dis Model Mech 2021;14:dmm048922. [PMID: 33787507 DOI: 10.1242/dmm.048922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
158 Kodukula K, Faller DV, Harpp DN, Kanara I, Pernokas J, Pernokas M, Powers WR, Soukos NS, Steliou K, Moos WH. Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us Something. Biores Open Access 2017;6:123-32. [PMID: 29098118 DOI: 10.1089/biores.2017.0020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
159 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
160 Liang H, Jiang F, Cheng R, Luo Y, Wang J, Luo Z, Li M, Shen X, He F. A high-fat diet and high-fat and high-cholesterol diet may affect glucose and lipid metabolism differentially through gut microbiota in mice. Exp Anim 2021;70:73-83. [PMID: 32999215 DOI: 10.1538/expanim.20-0094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
161 Ko JS. New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History. Pediatr Gastroenterol Hepatol Nutr 2019;22:501-10. [PMID: 31777715 DOI: 10.5223/pghn.2019.22.6.501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
162 Damhorst GL, Adelman MW, Woodworth MH, Kraft CS. Current Capabilities of Gut Microbiome-Based Diagnostics and the Promise of Clinical Application. J Infect Dis 2021;223:S270-5. [PMID: 33330938 DOI: 10.1093/infdis/jiaa689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Del Bas JM, Guirro M, Boqué N, Cereto A, Ras R, Crescenti A, Caimari A, Canela N, Arola L. Alterations in gut microbiota associated with a cafeteria diet and the physiological consequences in the host. Int J Obes (Lond) 2018;42:746-54. [PMID: 29167556 DOI: 10.1038/ijo.2017.284] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
164 Chen J, Zheng M, Liu J, Luo Y, Yang W, Yang J, Liu J, Zhou J, Xu C, Zhao F, Su M, Zang S, Shi J; on behalf of the Chinese NAFLD Clinical Research Network (CNAFLD CRN). Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis. Obesity 2019;27:2055-66. [DOI: 10.1002/oby.22627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
165 Rubio C, Puerto M, García-Rodríquez JJ, Lu VB, García-Martínez I, Alén R, Sanmartín-Salinas P, Toledo-Lobo MV, Saiz J, Ruperez J, Barbas C, Menchén L, Gribble FM, Reimann F, Guijarro LG, Carrascosa JM, Valverde ÁM. Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice. Mol Metab 2020;35:100954. [PMID: 32244182 DOI: 10.1016/j.molmet.2020.01.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
166 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
167 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
168 Burz SD, Monnoye M, Philippe C, Farin W, Ratziu V, Strozzi F, Paillarse JM, Chêne L, Blottière HM, Gérard P. Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). Microorganisms 2021;9:199. [PMID: 33477939 DOI: 10.3390/microorganisms9010199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
169 Wirbel J, Zych K, Essex M, Karcher N, Kartal E, Salazar G, Bork P, Sunagawa S, Zeller G. Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox. Genome Biol 2021;22:93. [PMID: 33785070 DOI: 10.1186/s13059-021-02306-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
170 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67:380-388. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 16.4] [Reference Citation Analysis]
171 Nagashimada M, Honda M. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. Int J Mol Sci 2021;22:8008. [PMID: 34360773 DOI: 10.3390/ijms22158008] [Reference Citation Analysis]
172 Qiao S, Bao L, Wang K, Sun S, Liao M, Liu C, Zhou N, Ma K, Zhang Y, Chen Y, Liu SJ, Liu H. Activation of a Specific Gut Bacteroides-Folate-Liver Axis Benefits for the Alleviation of Nonalcoholic Hepatic Steatosis. Cell Rep. 2020;32:108005. [PMID: 32783933 DOI: 10.1016/j.celrep.2020.108005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
173 Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68:359-370. [PMID: 30171065 DOI: 10.1136/gutjnl-2018-316307] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 28.8] [Reference Citation Analysis]
174 Nawrot M, Peschard S, Lestavel S, Staels B. Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism 2021;123:154844. [PMID: 34343577 DOI: 10.1016/j.metabol.2021.154844] [Reference Citation Analysis]
175 Fernandez-Cantos MV, Garcia-Morena D, Iannone V, El-Nezami H, Kolehmainen M, Kuipers OP. Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD. Tissue Barriers 2021;:1879719. [PMID: 34280073 DOI: 10.1080/21688370.2021.1879719] [Reference Citation Analysis]
176 Alves LF, Westmann CA, Lovate GL, de Siqueira GMV, Borelli TC, Guazzaroni ME. Metagenomic Approaches for Understanding New Concepts in Microbial Science. Int J Genomics 2018;2018:2312987. [PMID: 30211213 DOI: 10.1155/2018/2312987] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
177 Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15:425-439. [PMID: 29713021 DOI: 10.1038/s41575-018-0010-0] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 28.3] [Reference Citation Analysis]
178 Sharpton SR, Schnabl B, Knight R, Loomba R. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metab 2021;33:21-32. [PMID: 33296678 DOI: 10.1016/j.cmet.2020.11.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
179 Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, J G T Vehreschild M, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Mohr R, Lammert F, Tacke F, Schnabl B, Goeser T, Steffen HM, Demir M. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. Liver Int 2021;41:1576-91. [PMID: 33896117 DOI: 10.1111/liv.14899] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Yu L, Wang L, Wu X, Yi H. RSPO4-CRISPR alleviates liver injury and restores gut microbiota in a rat model of liver fibrosis. Commun Biol 2021;4:230. [PMID: 33603089 DOI: 10.1038/s42003-021-01747-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Mouzaki M, Loomba R. An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment. Curr Treat Options Gastroenterol 2020;18:270-80. [PMID: 33716495 DOI: 10.1007/s11938-020-00290-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Han M, Hao L, Lin Y, Li F, Wang J, Yang H, Xiao L, Kristiansen K, Jia H, Li J. A novel affordable reagent for room temperature storage and transport of fecal samples for metagenomic analyses. Microbiome 2018;6:43. [PMID: 29482661 DOI: 10.1186/s40168-018-0429-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
183 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
184 Krautkramer KA, Dhillon RS, Denu JM, Carey HV. Metabolic programming of the epigenome: host and gut microbial metabolite interactions with host chromatin. Transl Res 2017;189:30-50. [PMID: 28919341 DOI: 10.1016/j.trsl.2017.08.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
185 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020;158:1881-98. [PMID: 32044317 DOI: 10.1053/j.gastro.2020.01.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
186 Knudsen C, Neyrinck AM, Lanthier N, Delzenne NM. Microbiota and nonalcoholic fatty liver disease: promising prospects for clinical interventions? Curr Opin Clin Nutr Metab Care 2019;22:393-400. [PMID: 31219825 DOI: 10.1097/MCO.0000000000000584] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
187 Alferink LJM, Radjabzadeh D, Erler NS, Vojinovic D, Medina-Gomez C, Uitterlinden AG, de Knegt RJ, Amin N, Ikram MA, Janssen HLA, Kiefte-de Jong JC, Metselaar HJ, van Duijn CM, Kraaij R, Darwish Murad S. Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults.Hepatology. 2021;73:968-982. [PMID: 32530501 DOI: 10.1002/hep.31417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
188 Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba EV, Bettencourt R, Richards L, Yu RT, Atkins AR, Huan T, Brenner DA, Sirlin CB, Downes M, Evans RM, Loomba R. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell Metab 2020;32:878-888.e6. [PMID: 32610095 DOI: 10.1016/j.cmet.2020.06.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
189 Lynch SV, Ng SC, Shanahan F, Tilg H. Translating the gut microbiome: ready for the clinic? Nat Rev Gastroenterol Hepatol 2019;16:656-61. [PMID: 31562390 DOI: 10.1038/s41575-019-0204-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
190 Song CH, Kim N, Nam RH, Choi SI, Yu JE, Nho H, Surh YJ. Changes in Microbial Community Composition Related to Sex and Colon Cancer by Nrf2 Knockout. Front Cell Infect Microbiol 2021;11:636808. [PMID: 34249773 DOI: 10.3389/fcimb.2021.636808] [Reference Citation Analysis]
191 Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021;13:1442. [PMID: 33923255 DOI: 10.3390/nu13051442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
192 Wang Q, Lu Q, Shao W, Jiang Z, Hu H. Dysbiosis of gut microbiota after cholecystectomy is associated with non-alcoholic fatty liver disease in mice. FEBS Open Bio 2021. [PMID: 34184432 DOI: 10.1002/2211-5463.13243] [Reference Citation Analysis]
193 Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatol Res 2021;51:1013-25. [PMID: 34533266 DOI: 10.1111/hepr.13688] [Reference Citation Analysis]
194 Tripathi A, Xu ZZ, Xue J, Poulsen O, Gonzalez A, Humphrey G, Meehan MJ, Melnik AV, Ackermann G, Zhou D, Malhotra A, Haddad GG, Dorrestein PC, Knight R. Intermittent Hypoxia and Hypercapnia Reproducibly Change the Gut Microbiome and Metabolome across Rodent Model Systems. mSystems 2019;4:e00058-19. [PMID: 31058230 DOI: 10.1128/mSystems.00058-19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
195 Simon TG, Chan AT, Huttenhower C. Microbiome Biomarkers: One Step Closer in NAFLD Cirrhosis. Hepatology 2021;73:2063-6. [PMID: 33283299 DOI: 10.1002/hep.31660] [Reference Citation Analysis]
196 Noureddin M, Sanyal AJ. Pathogenesis of NASH: The Impact of Multiple Pathways. Curr Hepatol Rep 2018;17:350-60. [PMID: 31380156 DOI: 10.1007/s11901-018-0425-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
197 Manka P, Sydor S, Wase N, Best J, Brandenburg M, Hellbeck A, Schänzer J, Vilchez-Vargas R, Link A, Figge A, Jähnert A, von Arnim U, Coombes JD, Cubero FJ, Kahraman A, Kim MS, Kälsch J, Kinner S, Faber KN, Moshage H, Gerken G, Syn WK, Friedman SL, Canbay A, Bechmann LP. Anti-TNFα treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic status. Liver Int 2021. [PMID: 34219348 DOI: 10.1111/liv.15003] [Reference Citation Analysis]
198 Seneviratne CJ, Balan P, Suriyanarayanan T, Lakshmanan M, Lee DY, Rho M, Jakubovics N, Brandt B, Crielaard W, Zaura E. Oral microbiome-systemic link studies: perspectives on current limitations and future artificial intelligence-based approaches. Crit Rev Microbiol 2020;46:288-99. [PMID: 32434436 DOI: 10.1080/1040841X.2020.1766414] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
199 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
200 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 30.0] [Reference Citation Analysis]
201 Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
202 Molinaro A, Wahlström A, Marschall HU. Role of Bile Acids in Metabolic Control. Trends Endocrinol Metab 2018;29:31-41. [PMID: 29195686 DOI: 10.1016/j.tem.2017.11.002] [Cited by in Crossref: 128] [Cited by in F6Publishing: 123] [Article Influence: 25.6] [Reference Citation Analysis]
203 Giron F, Quigley EMM. Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective. J Neurogastroenterol Motil 2018;24:355-66. [PMID: 29684976 DOI: 10.5056/jnm18004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
204 Loftus M, Hassouneh SA, Yooseph S. Bacterial community structure alterations within the colorectal cancer gut microbiome. BMC Microbiol 2021;21:98. [PMID: 33789570 DOI: 10.1186/s12866-021-02153-x] [Reference Citation Analysis]
205 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
206 Komiyama S, Yamada T, Takemura N, Kokudo N, Hase K, Kawamura YI. Profiling of tumour-associated microbiota in human hepatocellular carcinoma. Sci Rep 2021;11:10589. [PMID: 34012007 DOI: 10.1038/s41598-021-89963-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
207 Cho SH, Cho YJ, Park JH. The human symbiont Bacteroides thetaiotaomicron promotes diet-induced obesity by regulating host lipid metabolism. J Microbiol 2022;60:118-27. [PMID: 34964947 DOI: 10.1007/s12275-022-1614-1] [Reference Citation Analysis]
208 Ahmed BA, Ong FJ, Barra NG, Blondin DP, Gunn E, Oreskovich SM, Szamosi JC, Syed SA, Hutchings EK, Konyer NB, Singh NP, Yabut JM, Desjardins EM, Anhê FF, Foley KP, Holloway AC, Noseworthy MD, Haman F, Carpentier AC, Surette MG, Schertzer JD, Punthakee Z, Steinberg GR, Morrison KM. Lower brown adipose tissue activity is associated with non-alcoholic fatty liver disease but not changes in the gut microbiota. Cell Rep Med 2021;2:100397. [PMID: 34622234 DOI: 10.1016/j.xcrm.2021.100397] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
209 Pan Y, Zhang X. Diet and gut microbiome in fatty liver and its associated liver cancer. J Gastroenterol Hepatol 2021. [PMID: 34664301 DOI: 10.1111/jgh.15713] [Reference Citation Analysis]
210 Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B, Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW, Sanyal AJ; TREAT Consortium. The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. Hepatology 2018;67:1284-302. [PMID: 29083504 DOI: 10.1002/hep.29623] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 14.5] [Reference Citation Analysis]
211 Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020;69:1483-91. [DOI: 10.1136/gutjnl-2019-318811] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 17.5] [Reference Citation Analysis]
212 Federici S, Suez J, Elinav E. Our Microbiome: On the Challenges, Promises, and Hype. In: Kloc M, editor. Symbiosis: Cellular, Molecular, Medical and Evolutionary Aspects. Cham: Springer International Publishing; 2020. pp. 539-57. [DOI: 10.1007/978-3-030-51849-3_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
213 Chrisman BS, Paskov KM, Stockham N, Jung JY, Varma M, Washington PY, Tataru C, Iwai S, DeSantis TZ, David M, Wall DP. Improved detection of disease-associated gut microbes using 16S sequence-based biomarkers. BMC Bioinformatics 2021;22:509. [PMID: 34666677 DOI: 10.1186/s12859-021-04427-7] [Reference Citation Analysis]
214 Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11: e9302. [PMID: 30591521 DOI: 10.15252/emmm.201809302] [Cited by in Crossref: 131] [Cited by in F6Publishing: 121] [Article Influence: 43.7] [Reference Citation Analysis]
215 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
216 Zhang H, Liang Y, Wu P, Shi X, Zhang G, Cai Z. Continuous Dermal Exposure to Triclocarban Perturbs the Homeostasis of Liver-Gut Axis in Mice: Insights from Metabolic Interactions and Microbiome Shifts. Environ Sci Technol 2021;55:5117-27. [PMID: 33691405 DOI: 10.1021/acs.est.0c08273] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
217 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
218 Paratore M, Santopaolo F, Cammarota G, Pompili M, Gasbarrini A, Ponziani FR. Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. J Clin Med 2021;10:2605. [PMID: 34204748 DOI: 10.3390/jcm10122605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol 2020;20:40-54. [DOI: 10.1038/s41577-019-0198-4] [Cited by in Crossref: 179] [Cited by in F6Publishing: 171] [Article Influence: 59.7] [Reference Citation Analysis]
220 Wang T, Guo XK, Xu H. Disentangling the Progression of Non-alcoholic Fatty Liver Disease in the Human Gut Microbiota. Front Microbiol 2021;12:728823. [PMID: 34721326 DOI: 10.3389/fmicb.2021.728823] [Reference Citation Analysis]
221 Ntandja Wandji LC, Gnemmi V, Mathurin P, Louvet A. Combined alcoholic and non-alcoholic steatohepatitis. JHEP Rep 2020;2:100101. [PMID: 32514497 DOI: 10.1016/j.jhepr.2020.100101] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
222 Vanuytsel T, Tack J, Farre R. The Role of Intestinal Permeability in Gastrointestinal Disorders and Current Methods of Evaluation. Front Nutr 2021;8:717925. [PMID: 34513903 DOI: 10.3389/fnut.2021.717925] [Reference Citation Analysis]
223 Mazzoccoli G, De Cosmo S, Mazza T. The Biological Clock: A Pivotal Hub in Non-alcoholic Fatty Liver Disease Pathogenesis. Front Physiol 2018;9:193. [PMID: 29662454 DOI: 10.3389/fphys.2018.00193] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
224 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
225 Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: a narrative review. Eur J Clin Nutr 2021. [PMID: 34584224 DOI: 10.1038/s41430-021-00991-6] [Reference Citation Analysis]
226 Fiorucci S, Biagioli M, Zampella A, Distrutti E. Bile Acids Activated Receptors Regulate Innate Immunity. Front Immunol 2018;9:1853. [PMID: 30150987 DOI: 10.3389/fimmu.2018.01853] [Cited by in Crossref: 123] [Cited by in F6Publishing: 118] [Article Influence: 30.8] [Reference Citation Analysis]
227 Carter JK, Bhattacharya D, Borgerding JN, Fiel MI, Faith JJ, Friedman SL. Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales. PLoS One 2021;16:e0244763. [PMID: 33395434 DOI: 10.1371/journal.pone.0244763] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
228 Bevivino A, Bacci G, Drevinek P, Nelson MT, Hoffman L, Mengoni A. Deciphering the Ecology of Cystic Fibrosis Bacterial Communities: Towards Systems-Level Integration. Trends Mol Med 2019;25:1110-22. [PMID: 31439509 DOI: 10.1016/j.molmed.2019.07.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
229 Gupta H, Suk KT, Kim DJ. Gut Microbiota at the Intersection of Alcohol, Brain, and the Liver. J Clin Med 2021;10:541. [PMID: 33540624 DOI: 10.3390/jcm10030541] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
230 Rodriguez J, Olivares M, Delzenne NM. Implication of the Gut Microbiota in Metabolic Inflammation Associated with Nutritional Disorders and Obesity. Mol Nutr Food Res 2021;65:e1900481. [PMID: 33111450 DOI: 10.1002/mnfr.201900481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Gheorghe G, Bungău S, Ceobanu G, Ilie M, Bacalbaşa N, Bratu OG, Vesa CM, Găman MA, Diaconu CC. The non-invasive assessment of hepatic fibrosis. J Formos Med Assoc 2021;120:794-803. [PMID: 32861550 DOI: 10.1016/j.jfma.2020.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
232 Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology 2021;73:126-43. [PMID: 32794259 DOI: 10.1002/hep.31523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
233 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610 [PMID: 34904031 DOI: 10.4254/wjh.v13.i11.1584] [Reference Citation Analysis]
234 Naito Y, Ushiroda C, Mizushima K, Inoue R, Yasukawa Z, Abe A, Takagi T. Epigallocatechin-3-gallate (EGCG) attenuates non-alcoholic fatty liver disease via modulating the interaction between gut microbiota and bile acids. J Clin Biochem Nutr 2020;67:2-9. [PMID: 32801462 DOI: 10.3164/jcbn.20-39] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
235 Martínez-Montoro JI, Cornejo-Pareja I, Gómez-Pérez AM, Tinahones FJ. Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:4077. [PMID: 34836332 DOI: 10.3390/nu13114077] [Reference Citation Analysis]
236 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
237 Hong CW, Hamilton G, Hooker C, Park CC, Tran CA, Henderson WC, Hooker JC, Fazeli Dehkordy S, Schwimmer JB, Reeder SB, Sirlin CB. Measurement of spleen fat on MRI-proton density fat fraction arises from reconstruction of noise. Abdom Radiol (NY) 2019;44:3295-303. [PMID: 31172210 DOI: 10.1007/s00261-019-02079-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
238 Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res 2018;7:F1000 Faculty Rev-921. [PMID: 30002817 DOI: 10.12688/f1000research.14841.1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
239 Iruzubieta P, Medina JM, Fernández-López R, Crespo J, de la Cruz F. A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. J Clin Med 2020;9:E1369. [PMID: 32392712 DOI: 10.3390/jcm9051369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
240 Flisiak-Jackiewicz M, Lebensztejn DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol 2019;5:11-21. [PMID: 30915402 DOI: 10.5114/ceh.2019.83152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
241 Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol 2021;18:167-80. [PMID: 33257833 DOI: 10.1038/s41575-020-00376-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
242 Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, Fragomeli V, Koay YC, Jackson M, O'Sullivan J, Weltman M, McCaughan G, El-Omar E, Zekry A. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021;12:187. [PMID: 33420074 DOI: 10.1038/s41467-020-20422-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
243 Papotto PH, Yilmaz B, Silva-Santos B. Crosstalk between γδ T cells and the microbiota. Nat Microbiol 2021;6:1110-7. [PMID: 34341528 DOI: 10.1038/s41564-021-00948-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 López-Moreno A, Acuña I, Torres-Sánchez A, Ruiz-Moreno Á, Cerk K, Rivas A, Suárez A, Monteoliva-Sánchez M, Aguilera M. Next Generation Probiotics for Neutralizing Obesogenic Effects: Taxa Culturing Searching Strategies. Nutrients 2021;13:1617. [PMID: 34065873 DOI: 10.3390/nu13051617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
246 Wu L, Li J, Feng J, Ji J, Yu Q, Li Y, Zheng Y, Dai W, Wu J, Guo C. Crosstalk between PPARs and gut microbiota in NAFLD. Biomed Pharmacother 2021;136:111255. [PMID: 33485064 DOI: 10.1016/j.biopha.2021.111255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
247 Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558-577. [PMID: 31622696 DOI: 10.1016/j.jhep.2019.10.003] [Cited by in Crossref: 141] [Cited by in F6Publishing: 151] [Article Influence: 47.0] [Reference Citation Analysis]
248 Chiang JYL, Ferrell JM. Bile Acids as Metabolic Regulators and Nutrient Sensors. Annu Rev Nutr 2019;39:175-200. [PMID: 31018107 DOI: 10.1146/annurev-nutr-082018-124344] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 17.3] [Reference Citation Analysis]
249 De Munck TJI, Xu P, Verwijs HJA, Masclee AAM, Jonkers D, Verbeek J, Koek GH. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis. Liver Int 2020;40:2906-16. [PMID: 33037768 DOI: 10.1111/liv.14696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
250 Kordy K, Li F, Lee DJ, Kinchen JM, Jew MH, La Rocque ME, Zabih S, Saavedra M, Woodward C, Cunningham NJ, Tobin NH, Aldrovandi GM. Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children. Front Microbiol 2021;12:713234. [PMID: 34475864 DOI: 10.3389/fmicb.2021.713234] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells 2020;9:E1005. [PMID: 32316690 DOI: 10.3390/cells9041005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
252 Sharpton SR, Yong GJM, Terrault NA, Lynch SV. Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:29-43. [PMID: 30619992 DOI: 10.1002/hep4.1284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
253 Phipps M, Wattacheril J. Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals. Frontline Gastroenterol 2020;11:478-83. [PMID: 33101626 DOI: 10.1136/flgastro-2018-101119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
254 Kriss M, Verna EC, Rosen HR, Lozupone CA. Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes. Transplantation 2019;103:668-78. [PMID: 30507741 DOI: 10.1097/TP.0000000000002568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
255 Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Moyses HE, Clough GF, Wright M, Patel J, Bindels L, Delzenne NM, Calder PC, Byrne CD. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. Contemp Clin Trials 2018;71:113-23. [PMID: 29787859 DOI: 10.1016/j.cct.2018.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
256 Villard A, Boursier J, Andriantsitohaina R. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis? Am J Physiol Gastrointest Liver Physiol 2021;320:G485-95. [PMID: 33471632 DOI: 10.1152/ajpgi.00362.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
257 Hendrikx T, Schnabl B. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. J Intern Med 2019;286:32-40. [PMID: 30873652 DOI: 10.1111/joim.12892] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
258 Yang G, Wei J, Liu P, Zhang Q, Tian Y, Hou G, Meng L, Xin Y, Jiang X. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism 2021;117:154712. [PMID: 33497712 DOI: 10.1016/j.metabol.2021.154712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
259 Karagöz MA, Nalbantoglu OU. Taxonomic classification of metagenomic sequences from Relative Abundance Index profiles using deep learning. Biomedical Signal Processing and Control 2021;67:102539. [DOI: 10.1016/j.bspc.2021.102539] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
260 Khan S, Luck H, Winer S, Winer DA. Emerging concepts in intestinal immune control of obesity-related metabolic disease. Nat Commun 2021;12:2598. [PMID: 33972511 DOI: 10.1038/s41467-021-22727-7] [Reference Citation Analysis]
261 Dongiovanni P, Valenti L. A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2017;18:E1534. [PMID: 28714900 DOI: 10.3390/ijms18071534] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
262 Tranah TH, Edwards LA, Schnabl B, Shawcross DL. Targeting the gut-liver-immune axis to treat cirrhosis. Gut 2021;70:982-94. [PMID: 33060124 DOI: 10.1136/gutjnl-2020-320786] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
263 Dai X, Hou H, Zhang W, Liu T, Li Y, Wang S, Wang B, Cao H. Microbial Metabolites: Critical Regulators in NAFLD.Front Microbiol. 2020;11:567654. [PMID: 33117316 DOI: 10.3389/fmicb.2020.567654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
264 Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, Sanguinetti M, Morelli D, Paroni Sterbini F, Petito V, Reddel S, Calvani R, Camisaschi C, Picca A, Tuccitto A, Gasbarrini A, Pompili M, Mazzaferro V. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology 2019;69:107-20. [DOI: 10.1002/hep.30036] [Cited by in Crossref: 155] [Cited by in F6Publishing: 168] [Article Influence: 38.8] [Reference Citation Analysis]
265 Moreira GV, Azevedo FF, Ribeiro LM, Santos A, Guadagnini D, Gama P, Liberti EA, Saad M, Carvalho C. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. J Nutr Biochem 2018;62:143-54. [PMID: 30292107 DOI: 10.1016/j.jnutbio.2018.07.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
266 Pandak WM, Kakiyama G. The acidic pathway of bile acid synthesis: Not just an alternative pathway. Liver Res 2019;3:88-98. [PMID: 32015930 DOI: 10.1016/j.livres.2019.05.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
267 Pelusi S, Valenti L. Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. Liver Int 2019;39:250-6. [DOI: 10.1111/liv.13972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
268 Bastian WP, Hasan I, Lesmana CRA, Rinaldi I, Gani RA. Gut Microbiota Profiles in Nonalcoholic Fatty Liver Disease and Its Possible Impact on Disease Progression Evaluated with Transient Elastography: Lesson Learnt from 60 Cases. Case Rep Gastroenterol 2019;13:125-33. [PMID: 31011312 DOI: 10.1159/000498946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
269 Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
270 Uchiyama K, Naito Y, Takagi T. Intestinal microbiome as a novel therapeutic target for local and systemic inflammation. Pharmacol Ther 2019;199:164-72. [PMID: 30877020 DOI: 10.1016/j.pharmthera.2019.03.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
271 Asadipooya K, Lankarani KB, Raj R, Kalantarhormozi M. RAGE is a Potential Cause of Onset and Progression of Nonalcoholic Fatty Liver Disease. Int J Endocrinol 2019;2019:2151302. [PMID: 31641351 DOI: 10.1155/2019/2151302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
272 Caussy C, Hsu C, Lo MT, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen CH, Loomba R; Genetics of NAFLD in Twins Consortium. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018;68:918-932. [PMID: 29572891 DOI: 10.1002/hep.29892] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
273 Guohong-liu, Qingxi-zhao, Hongyun-wei. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Annals of Hepatology 2019;18:796-803. [DOI: 10.1016/j.aohep.2019.06.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
274 Wu S, Jiang P, Zhao XM, Chen WH. Treatment regimens may compromise gut-microbiome-derived signatures for liver cirrhosis. Cell Metab 2021;33:455-6. [PMID: 33657385 DOI: 10.1016/j.cmet.2021.02.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
275 Han R, Qiu H, Zhong J, Zheng N, Li B, Hong Y, Ma J, Wu G, Chen L, Sheng L, Li H. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota. Phytomedicine 2021;85:153544. [PMID: 33773192 DOI: 10.1016/j.phymed.2021.153544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
276 Ushiroda C, Naito Y, Takagi T, Uchiyama K, Mizushima K, Higashimura Y, Yasukawa Z, Okubo T, Inoue R, Honda A, Matsuzaki Y, Itoh Y. Green tea polyphenol (epigallocatechin-3-gallate) improves gut dysbiosis and serum bile acids dysregulation in high-fat diet-fed mice. J Clin Biochem Nutr. 2019;65:34-46. [PMID: 31379412 DOI: 10.3164/jcbn.18-116] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
277 Lang S, Farowski F, Martin A, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Lammert F, Goeser T, Steffen HM, Demir M. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools. Sci Rep 2020;10:9385. [PMID: 32523101 DOI: 10.1038/s41598-020-66241-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
278 Ikegami T, Honda A. Reciprocal interactions between bile acids and gut microbiota in human liver diseases: Bile acids and gut microbiota. Hepatol Res 2018;48:15-27. [DOI: 10.1111/hepr.13001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
279 Kong CY, Li ZM, Han B, Zhang ZY, Chen HL, Zhang SL, Xu JQ, Mao YQ, Zhao YP, Wang LS. Diet Consisting of Balanced Yogurt, Fruit, and Vegetables Modifies the Gut Microbiota and Protects Mice against Nonalcoholic Fatty Liver Disease. Mol Nutr Food Res 2019;63:e1900249. [PMID: 31271251 DOI: 10.1002/mnfr.201900249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
280 Ruuskanen MO, Åberg F, Männistö V, Havulinna AS, Méric G, Liu Y, Loomba R, Vázquez-Baeza Y, Tripathi A, Valsta LM, Inouye M, Jousilahti P, Salomaa V, Jain M, Knight R, Lahti L, Niiranen TJ. Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes 2021;13:1-22. [PMID: 33651661 DOI: 10.1080/19490976.2021.1888673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
281 Zhu L, Baker RD, Zhu R, Baker SS. Sequencing the gut metagenome as a noninvasive diagnosis for advanced nonalcoholic steatohepatitis. Hepatology. 2017;66:2080-2083. [PMID: 28732121 DOI: 10.1002/hep.29387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
282 Riazi K, Raman M, Taylor L, Swain MG, Shaheen AA. Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer? Nutrients 2019;11:E2878. [PMID: 31779112 DOI: 10.3390/nu11122878] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
283 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
284 Nayfach S, Shi ZJ, Seshadri R, Pollard KS, Kyrpides NC. New insights from uncultivated genomes of the global human gut microbiome. Nature 2019;568:505-10. [PMID: 30867587 DOI: 10.1038/s41586-019-1058-x] [Cited by in Crossref: 232] [Cited by in F6Publishing: 163] [Article Influence: 77.3] [Reference Citation Analysis]
285 Satapathy SK, Banerjee P, Pierre JF, Higgins D, Dutta S, Heda R, Khan SD, Mupparaju VK, Mas V, Nair S, Eason JD, Kleiner DE, Maluf DG. Characterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis. Transplant Direct 2020;6:e625. [PMID: 33204823 DOI: 10.1097/TXD.0000000000001033] [Reference Citation Analysis]
286 Zheng Z, Wang B. The Gut-Liver Axis in Health and Disease: The Role of Gut Microbiota-Derived Signals in Liver Injury and Regeneration. Front Immunol 2021;12:775526. [PMID: 34956204 DOI: 10.3389/fimmu.2021.775526] [Reference Citation Analysis]
287 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
288 Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 2021;56:951-63. [PMID: 34533632 DOI: 10.1007/s00535-021-01796-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Huang W, Kong D. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. Biomedicine & Pharmacotherapy 2021;135:111235. [DOI: 10.1016/j.biopha.2021.111235] [Reference Citation Analysis]
290 Zhao M, Zhao L, Xiong X, He Y, Huang W, Liu Z, Ji L, Pan B, Guo X, Wang L, Cheng S, Xu M, Yang H, Yin Y, Garcia-barrio MT, Chen YE, Meng X, Zheng L. TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice. Gastroenterology 2020;158:2266-2281.e27. [DOI: 10.1053/j.gastro.2020.02.033] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
291 Zheng J, Zhu L, Hu B, Zou X, Hu H, Zhang Z, Jiang N, Ma J, Yang H, Liu H. 1-Deoxynojirimycin improves high fat diet-induced nonalcoholic steatohepatitis by restoring gut dysbiosis. J Nutr Biochem 2019;71:16-26. [PMID: 31272028 DOI: 10.1016/j.jnutbio.2019.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
292 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 301] [Cited by in F6Publishing: 300] [Article Influence: 100.3] [Reference Citation Analysis]
293 Zhang L, Xie Z, Yu H, Du H, Wang X, Cai J, Qiu Y, Chen R, Jiang X, Liu Z, Li Y, Chen T. TLR2 inhibition ameliorates the amplification effect of LPS on lipid accumulation and lipotoxicity in hepatic cells. Ann Transl Med 2021;9:1429. [PMID: 34733981 DOI: 10.21037/atm-21-4012] [Reference Citation Analysis]
294 Mardinoglu A, Wu H, Bjornson E, Zhang C, Hakkarainen A, Räsänen SM, Lee S, Mancina RM, Bergentall M, Pietiläinen KH, Söderlund S, Matikainen N, Ståhlman M, Bergh PO, Adiels M, Piening BD, Granér M, Lundbom N, Williams KJ, Romeo S, Nielsen J, Snyder M, Uhlén M, Bergström G, Perkins R, Marschall HU, Bäckhed F, Taskinen MR, Borén J. An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. Cell Metab 2018;27:559-571.e5. [PMID: 29456073 DOI: 10.1016/j.cmet.2018.01.005] [Cited by in Crossref: 161] [Cited by in F6Publishing: 149] [Article Influence: 40.3] [Reference Citation Analysis]
295 Yang R, Shang J, Zhou Y, Liu W, Tian Y, Shang H. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:1401-9. [PMID: 34877910 DOI: 10.1080/17474124.2022.2016391] [Reference Citation Analysis]
296 Caussy C, Loomba R. Gut microbiome, microbial metabolites and the development of NAFLD. Nat Rev Gastroenterol Hepatol 2018;15:719-20. [PMID: 30158571 DOI: 10.1038/s41575-018-0058-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
297 Aoki R, Onuki M, Hattori K, Ito M, Yamada T, Kamikado K, Kim YG, Nakamoto N, Kimura I, Clarke JM, Kanai T, Hase K. Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. Microbiome 2021;9:188. [PMID: 34530928 DOI: 10.1186/s40168-021-01125-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
298 Eisenstein M. Diagnostics: Missing the point. Nature 2017;551. [PMID: 29168832 DOI: 10.1038/d41586-017-06048-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
299 Mukherjee A, Lordan C, Ross RP, Cotter PD. Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut Microbes 2020;12:1802866. [PMID: 32835590 DOI: 10.1080/19490976.2020.1802866] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
300 Guo J, Fang W, Chen X, Lin Y, Hu G, Wei J, Zhang X, Yang C, Li J. Upstream stimulating factor 1 suppresses autophagy and hepatic lipid droplet catabolism by activating mTOR. FEBS Lett 2018;592:2725-38. [PMID: 30054905 DOI: 10.1002/1873-3468.13203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
301 Fling RR, Zacharewski TR. Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:12431. [PMID: 34830313 DOI: 10.3390/ijms222212431] [Reference Citation Analysis]
302 Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
303 Mehal WZ, Loomba R. The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis. Hepatology 2019;70:741-4. [PMID: 30779368 DOI: 10.1002/hep.30577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Sookoian S, Pirola CJ. Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. Hepatobiliary Surg Nutr 2021;10:337-49. [PMID: 34159161 DOI: 10.21037/hbsn-20-270] [Reference Citation Analysis]
305 Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
306 Cassano M, Dufour J. Inflammation and Microbiota Fingerprint: Delphi’s Oracle for Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma? Hepatology 2019;69:12-5. [DOI: 10.1002/hep.30267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
307 Hassouneh SA, Loftus M, Yooseph S. Linking Inflammatory Bowel Disease Symptoms to Changes in the Gut Microbiome Structure and Function. Front Microbiol 2021;12:673632. [PMID: 34349736 DOI: 10.3389/fmicb.2021.673632] [Reference Citation Analysis]
308 Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis 2021;41:191-205. [PMID: 34107545 DOI: 10.1055/s-0041-1723752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Lanthier N, Rodriguez J, Nachit M, Hiel S, Trefois P, Neyrinck AM, Cani PD, Bindels LB, Thissen JP, Delzenne NM. Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients. Sci Rep 2021;11:659. [PMID: 33436764 DOI: 10.1038/s41598-020-79718-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
310 Beraza N. Fibrosis and the intestinal microbiome; a focus on chronic liver disease. Curr Opin Pharmacol 2019;49:76-81. [PMID: 31670055 DOI: 10.1016/j.coph.2019.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
311 Acharya C, Bajaj JS. Altered Microbiome in Patients With Cirrhosis and Complications. Clin Gastroenterol Hepatol 2019;17:307-21. [PMID: 30099098 DOI: 10.1016/j.cgh.2018.08.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
312 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1264-1281.e4. [PMID: 30660725 DOI: 10.1053/j.gastro.2018.12.036] [Cited by in Crossref: 310] [Cited by in F6Publishing: 296] [Article Influence: 103.3] [Reference Citation Analysis]
313 Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, Kang H, Park JH, Kim JH, Lee DH, Lee S, Kim W, Ko G. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun 2020;11:4982. [PMID: 33020474 DOI: 10.1038/s41467-020-18754-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
314 Marfil-Sánchez A, Zhang L, Alonso-Pernas P, Mirhakkak M, Mueller M, Seelbinder B, Ni Y, Santhanam R, Busch A, Beemelmanns C, Ermolaeva M, Bauer M, Panagiotou G. An integrative understanding of the large metabolic shifts induced by antibiotics in critical illness. Gut Microbes 2021;13:1993598. [PMID: 34793277 DOI: 10.1080/19490976.2021.1993598] [Reference Citation Analysis]
315 Rupcic Rubin V, Bojanic K, Smolic M, Rubin J, Tabll A, Smolic R. An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents. J Clin Transl Hepatol 2021;9:60-70. [PMID: 33604256 DOI: 10.14218/JCTH.2020.00040] [Reference Citation Analysis]
316 Chalasani N, Toden S, Sninsky JJ, Rava RP, Braun JV, Gawrieh S, Zhuang J, Nerenberg M, Quake SR, Maddala T. Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization. Am J Physiol Gastrointest Liver Physiol 2021;320:G439-49. [PMID: 33501884 DOI: 10.1152/ajpgi.00397.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
317 Kronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 2021:S0168-8278(21)02180-2. [PMID: 34800610 DOI: 10.1016/j.jhep.2021.11.008] [Reference Citation Analysis]
318 Ezzaidi N, Zhang X, Coker OO, Yu J. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer. Cancer Lett 2019;459:186-91. [PMID: 31185249 DOI: 10.1016/j.canlet.2019.114425] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
319 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
320 Si J, Lee G, You HJ, Joo SK, Lee DH, Ku BJ, Park S, Kim W, Ko G. Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease. Comput Struct Biotechnol J 2021;19:5920-30. [PMID: 34849196 DOI: 10.1016/j.csbj.2021.10.032] [Reference Citation Analysis]
321 Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res 2020;50:817-30. [PMID: 32323426 DOI: 10.1111/hepr.13506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
322 Albhaisi S, Sanyal AJ. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceut Med 2019;33:451-63. [PMID: 31933238 DOI: 10.1007/s40290-019-00305-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
323 Hendrikx T, Schnabl B. Antimicrobial proteins: intestinal guards to protect against liver disease. J Gastroenterol 2019;54:209-17. [PMID: 30392013 DOI: 10.1007/s00535-018-1521-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
324 Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J, Liu H. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol 2020;55:142-58. [PMID: 31845054 DOI: 10.1007/s00535-019-01649-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
325 Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R. Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. Clin Gastroenterol Hepatol 2019;17:218-30. [PMID: 30240894 DOI: 10.1016/j.cgh.2018.09.017] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 18.8] [Reference Citation Analysis]
326 Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021;6:578-88. [PMID: 33961787 DOI: 10.1016/S2468-1253(21)00020-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
327 Arab JP, Arrese M, Shah VH. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. Hepatol Res 2020;50:407-18. [PMID: 31840358 DOI: 10.1111/hepr.13473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
328 Adolph TE, Grander C, Moschen AR, Tilg H. Liver–Microbiome Axis in Health and Disease. Trends in Immunology 2018;39:712-23. [DOI: 10.1016/j.it.2018.05.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 14.3] [Reference Citation Analysis]
329 Grabherr F, Grander C, Effenberger M, Adolph TE, Tilg H. Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2019;10:611. [PMID: 31555219 DOI: 10.3389/fendo.2019.00611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
330 Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, Yki-järvinen H, Grønbæk H, Cortez-pinto H, George J, Fan J, Valenti L, Abdelmalek M, Romero-gomez M, Rinella M, Arrese M, Eslam M, Bedossa P, Newsome PN, Anstee QM, Jalan R, Bataller R, Loomba R, Sookoian S, Sarin SK, Harrison S, Kawaguchi T, Wong VW, Ratziu V, Yilmaz Y, Younossi Z. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020;158:1999-2014.e1. [DOI: 10.1053/j.gastro.2019.11.312] [Cited by in Crossref: 428] [Cited by in F6Publishing: 423] [Article Influence: 214.0] [Reference Citation Analysis]
331 Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. Mol Aspects Med 2019;65:2-15. [PMID: 29958900 DOI: 10.1016/j.mam.2018.06.003] [Cited by in Crossref: 132] [Cited by in F6Publishing: 135] [Article Influence: 33.0] [Reference Citation Analysis]
332 Adolph TE, Effenberger M, Tilg H. How our understanding of the microbiome has changed the way we look at liver diseases. Biomark Med 2018;12:1203-6. [PMID: 30444134 DOI: 10.2217/bmm-2018-0266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
333 Long MT, Gandhi S, Loomba R. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism 2020;111S:154259. [PMID: 32387227 DOI: 10.1016/j.metabol.2020.154259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
334 Cabrera-Rubio R, Patterson AM, Cotter PD, Beraza N. Cholestasis induced by bile duct ligation promotes changes in the intestinal microbiome in mice. Sci Rep 2019;9:12324. [PMID: 31444478 DOI: 10.1038/s41598-019-48784-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
335 Balsano C, Alisi A, Brunetto MR, Invernizzi P, Burra P, Piscaglia F; Special Interest Group (SIG) Artificial Intelligence and Liver Diseases; Italian Association for the Study of the Liver (AISF). The application of artificial intelligence in hepatology: A systematic review. Dig Liver Dis 2021:S1590-8658(21)00317-0. [PMID: 34266794 DOI: 10.1016/j.dld.2021.06.011] [Reference Citation Analysis]
336 Gu X, Lu Q, Zhang C, Tang Z, Chu L. Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review. Semin Liver Dis 2021. [PMID: 34261137 DOI: 10.1055/s-0041-1732319] [Reference Citation Analysis]
337 Zhai Q, Cen S, Jiang J, Zhao J, Zhang H, Chen W. Disturbance of trace element and gut microbiota profiles as indicators of autism spectrum disorder: A pilot study of Chinese children. Environmental Research 2019;171:501-9. [DOI: 10.1016/j.envres.2019.01.060] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 12.0] [Reference Citation Analysis]
338 Kang GU, Ibal JC, Lee S, Jang MH, Park YJ, Kim MC, Park TH, Kim MS, Kim RH, Shin JH. Alteration of the Soil Microbiota in Ginseng Rusty Roots: Application of Machine Learning Algorithm to Explore Potential Biomarkers for Diagnostic and Predictive Analytics. J Agric Food Chem 2021;69:8298-306. [PMID: 34043355 DOI: 10.1021/acs.jafc.1c01314] [Reference Citation Analysis]
339 Fernández-Veledo S, Ceperuelo-Mallafré V, Vendrell J. Rethinking succinate: an unexpected hormone-like metabolite in energy homeostasis. Trends Endocrinol Metab 2021;32:680-92. [PMID: 34301438 DOI: 10.1016/j.tem.2021.06.003] [Reference Citation Analysis]
340 Motta BM, Grander C, Gögele M, Foco L, Vukovic V, Melotti R, Fuchsberger C, De Grandi A, Cantaloni C, Picard A, Mascalzoni D, Rossini A, Pattaro C, Tilg H, Pramstaller PP. Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study. J Transl Med 2019;17:408. [PMID: 31801616 DOI: 10.1186/s12967-019-02130-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
341 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2021;69:1691-705. [DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 26.5] [Reference Citation Analysis]
342 Giraud J, Saleh M. Host-Microbiota Interactions in Liver Inflammation and Cancer. Cancers (Basel) 2021;13:4342. [PMID: 34503151 DOI: 10.3390/cancers13174342] [Reference Citation Analysis]
343 Shomorony I, Cirulli ET, Huang L, Napier LA, Heister RR, Hicks M, Cohen IV, Yu HC, Swisher CL, Schenker-Ahmed NM, Li W, Nelson KE, Brar P, Kahn AM, Spector TD, Caskey CT, Venter JC, Karow DS, Kirkness EF, Shah N. An unsupervised learning approach to identify novel signatures of health and disease from multimodal data. Genome Med 2020;12:7. [PMID: 31924279 DOI: 10.1186/s13073-019-0705-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
344 Li J, Cha R, Zhao X, Guo H, Luo H, Wang M, Zhou F, Jiang X. Gold Nanoparticles Cure Bacterial Infection with Benefit to Intestinal Microflora. ACS Nano 2019;13:5002-14. [PMID: 30916928 DOI: 10.1021/acsnano.9b01002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
345 Iino C, Endo T, Mikami K, Hasegawa T, Kimura M, Sawada N, Nakaji S, Fukuda S. Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study. Hepatol Int 2019;13:748-56. [DOI: 10.1007/s12072-019-09987-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
346 Jiang L, Schnabl B. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know? Physiology (Bethesda) 2020;35:261-74. [PMID: 32490750 DOI: 10.1152/physiol.00005.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
347 Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L, Hrabar D, Smircic Duvnjak L. New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis. J Clin Transl Hepatol 2021;9:51-9. [PMID: 33604255 DOI: 10.14218/JCTH.2020.00057] [Reference Citation Analysis]
348 Naseri M, Houri H, Yadegar A, Asadzadeh Aghdaei H, Zahiri J. Investigation of etiology-specific alterations in the gut microbiota in liver cirrhosis. Expert Rev Gastroenterol Hepatol 2021;:1-7. [PMID: 34632902 DOI: 10.1080/17474124.2021.1991312] [Reference Citation Analysis]
349 Barrow F, Khan S, Fredrickson G, Wang H, Dietsche K, Parthiban P, Robert S, Kaiser T, Winer S, Herman A, Adeyi O, Mouzaki M, Khoruts A, Hogquist KA, Staley C, Winer DA, Revelo XS. Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling. Hepatology 2021;74:704-22. [PMID: 33609303 DOI: 10.1002/hep.31755] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
350 Mouzaki M, Loomba R. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol 2019;12:1756284819858470. [PMID: 31258623 DOI: 10.1177/1756284819858470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
351 Tan H, Nie S. Functional hydrocolloids, gut microbiota and health: picking food additives for personalized nutrition. FEMS Microbiol Rev 2021:fuaa065. [PMID: 33512498 DOI: 10.1093/femsre/fuaa065] [Reference Citation Analysis]
352 Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021;119:154770. [PMID: 33864798 DOI: 10.1016/j.metabol.2021.154770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
353 Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377-386. [PMID: 31024089 DOI: 10.1038/s41575-019-0144-8] [Cited by in Crossref: 144] [Cited by in F6Publishing: 132] [Article Influence: 48.0] [Reference Citation Analysis]
354 Adams LA, Wang Z, Liddle C, Melton PE, Ariff A, Chandraratna H, Tan J, Ching H, Coulter S, de Boer B, Christophersen CT, O'Sullivan TA, Morrison M, Jeffrey GP. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2020;40:1356-65. [PMID: 32243703 DOI: 10.1111/liv.14453] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]